U.S. flag

An official website of the United States government

GTR Home > Tests > +RNAinsight® for Penn Cancer Grant Panel

Performance Characteristics

Availability

Help

  • Entire test performed in-house

Analytical Validity

Help

This test is designed and validated to be capable of detecting >99% of described mutations in the gene(s) represented.

Citations

Not provided

Proficiency Testing (PT)

Is proficiency testing performed for this test? Help
No
PT ProviderHelp
N/A

FDA Regulatory Clearances of the Test

Help
FDA Category Designation
FDA exercises enforcement discretion

Suggested reading

Practice guidelines

  • NCCN, 2023
    NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colon Cancer, 2023
  • ACMG ACT, 2019
    American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, APC Pathogenic Variants (Familial Adenomatous Polyposis [FAP]), 2019
  • ACMG ACT, 2012
    American College of Medical Genetics and Genomics Family History ACT Sheet, Colon Cancer (Asymptomatic), 2012
  • EuroGenetest, 2011
    Clinical utility gene card for: familial adenomatous polyposis (FAP) and attenuated FAP (AFAP).

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.